Pre-trial of Clinical Trial of Traditional Chinese Medicine Treatment for Elderly Patients With Coronary Heart Disease Who Are Still Symptomatic After Optimal Medical Treatment

NCT ID: NCT07041359

Last Updated: 2025-09-29

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE4
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-08-18
• Study Completion Date: 2026-12-31

Brief Summary

To explore the effectiveness of compound Danshen Dripping Pill and Qishen Yiqi Dripping Pill in the elderly population with coronary heart disease and the safety of multiple medications

Detailed Description

This study is a prospective, double-blind, randomized controlled clinical trial, which aims to explore the effectiveness and safety of polypharmacy in the elderly population of stable angina patients, and make up for the limitations of clinical treatment. As commonly used traditional Chinese medicine preparations, the efficacy and safety of compound Danshen Dripping Pill and Qishen Yiqi Dripping Pill have been supported by previous studies, providing a solid theoretical basis. The study design adopts scientific and reliable clinical trial methods, and the treatment plan combines Western medicine treatment and traditional Chinese medicine intervention, which has high clinical application value. In the actual clinical treatment, due to the complex medical history of elderly patients, they often have multi-vessel coronary artery lesions, and the treatment tolerance is worse than that of young people, so although they are accompanied by angina pectoris, the treatment methods are relatively limited. This study provides evidence of the efficacy and safety of drugs for the treatment of elderly patients with angina pectoris through the combination of Chinese and Western treatments, which can help make up for the dilemma of limited clinical treatment methods.

Conditions

Coronary Arterial Disease (CAD)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Qi stagnation and blood stasis type control group

Intervention with placebo on the Basis of optimal medical treatment

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Intervention with placebo on the Basis of optimal medical treatment

Qi stagnation and blood stasis type experimental group

Intervention with Compound Danshen Dripping Pills on the Basis of optimal medical treatment

Group Type: EXPERIMENTAL

Compound Danshen Dripping Pills

Intervention Type: DRUG

The experimental group used compound Danshen dripping pills as an intervention on the basis of conventional western medicine treatment.

Qi deficiency and blood stasis type control group

Intervention with placebo on the Basis of optimal medical treatment

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Intervention with placebo on the Basis of optimal medical treatment

Qi deficiency and blood stasis type experimental group

Intervention with Qishen Yiqi Dropping Pills on the basis of conventional western medicine treatment

Group Type: EXPERIMENTAL

Qishen Yiqi Drop Pills

Intervention Type: DRUG

The experimental group used Qishen Yiqi dripping pills as an intervention on the basis of conventional western medicine treatment.

Interventions

Compound Danshen Dripping Pills

The experimental group used compound Danshen dripping pills as an intervention on the basis of conventional western medicine treatment.

Intervention Type: DRUG

Qishen Yiqi Drop Pills

The experimental group used Qishen Yiqi dripping pills as an intervention on the basis of conventional western medicine treatment.

Intervention Type: DRUG

Placebo

Intervention with placebo on the Basis of optimal medical treatment

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. 75 years old ≤ age < 90 years old, regardless of gender;

2. Patients who meet the diagnostic criteria for angina pectoris, including patients with typical or atypical angina pectoris: discomfort in the anterior region is triggered by physical activity or emotional excitement and can be relieved by rest or taking nitroglycerin.Those who meet two or more of the above characteristics. After receiving conventional Western medicine treatment, the symptoms did not improve significantly or the treatment effect is poor.

3. Meet the diagnostic criteria for multiple coronary artery disease with the number of coronary artery disease being greater than or equal to two (defined as angiographically the right coronary artery, left circumflex artery or left anterior descending artery stenosis rate was greater than 50%), and the patient refused or could not tolerate coronary artery revascularization or one or more coronary arteries still have a stenosis rate of ≥50% after partial revascularization;

4. The patient is in line with the qi stagnation and blood stasis type or qi deficiency and blood stasis type in the TCM syndrome classification. If the results of the two syndrome differentiation are inconsistent, the TCM experts will review the syndrome differentiation, and the syndrome differentiation classification of the TCM experts shall prevail.

5. The patient has good communication skills, can understand and provide relevant information required for the study, and is aware of the research purpose, content, possible risks and expected benefits can be fully provided with relevant information required for this research. Patients and their families voluntarily participated and agreed to sign the informed consent.

Exclusion Criteria

1. Those who have had acute coronary syndrome within the past month

2. Acute myocardial infarction, acute myocarditis, severe arrhythmia, aortic dissecction, pericarditis, heart failure (NYHA heart function class Ⅲ or IV, EF ≤ 30%), cardiogenic shock in past 3 months or patients with chest tightness and chest pain caused by other diseases such as severe valvular disease, etc.

3. Combined with acute pulmonary embolism, acute cerebral hemorrhage, polyarteritis, severe hematologic diseases, severe infectious diseases, severe immune dysfunction, malignant tumors, other organ failure or expected life expectancy less than 1 year

4. Severe primary disease or severe dysfunction of the liver or kidneys（ALT levels exceeding 3.0 times the upper limit of normal or eGFR ≤30 mL/min/1.73 m²）

5. Patients with severe mental disorder

6. Those who are allergic to the test drug

7. Patients who have participated in other clinical trials in the past month

8. Patients who have taken anticoagulants such as warfarin, new oral anticoagulants (NOAC) or traditional Chinese medicine preparations for promoting blood circulation and removing blood stasis in the past month

9. Refusal to sign informed consent

• Minimum Eligible Age: 75 Years
• Maximum Eligible Age: 90 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

China National Center for Cardiovascular Diseases

OTHER_GOV

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Fuwai hospital, CAMS&PUMC

Beijing, Beijing Municipality, China

Site Status: RECRUITING

Countries

China

Facility Contacts

Yongjian Wu

Role: primary

fuwaiwyj@163.com

13701387189

Other Identifiers

2024-ZX080

Identifier Type: -

Identifier Source: org_study_id